MAPK13 and B-cell chronic lymphocytic leukemia: We could also identify differences in the BcR signaling pathway between M-CLL and U-CLL, specific to the context of trisomy 12; with U-CLL, trisomy 12 cases exhibiting a further increase of the intracellular components of the pathway (e.g. NFKB1, MAPK13), and M-CLL, trisomy 12 exhibiting an increase of membrane-bound components (e.g. CD21, CD79A/B, Supplementary Fig. 9e).